secwatch.observer — SEC 8-K summary
======================================

Issuer:     Biohaven Ltd. (BHVN)
CIK:        0001935979
Form:       8-K
Filed at:   2024-05-09T23:59:59+00:00
Accession:  0001935979-24-000047
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Biohaven Q1 net loss $179.5M ($2.20/shr) vs $70.5M loss a year ago; cash $287.6M plus $247.8M from April offering
--------------------------------------------------------------------------------

- Net loss $179.5M ($2.20/shr); non-GAAP adjusted net loss $144.6M ($1.77/shr); both more than doubled vs Q1 2023.
- R&D expense $156.0M, up 146% YoY, driven by advancing trials and $16.6M in shares for Pyramid Biosciences acquisition.
- Cash, equivalents and marketable securities $287.6M at March 31; additional $247.8M from April 2024 public offering of 6.45M shares at $41.
- FDA granted rare pediatric disease designation for taldefgrobep alfa in SMA; Phase 3 data expected 2H 2024.
- Phase 2/3 programs initiated with Kv7 activator BHV-7000 in epilepsy, MDD, and bipolar; BHV-1300 MoDE shows IgG reduction.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1935979/000193597924000047/0001935979-24-000047-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1935979/000193597924000047/bhvn-20240509.htm
  HTML page:      https://secwatch.observer/filing/0001935979-24-000047

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer